Company Overview: DeepKinase Technology Co., Ltd, branded as “Danbai Zhi,” is a functional proteomics technology platform company dedicated to advancing precision medicine and drug discovery. Founded in 2019 by a group of high-level scientists, seasoned industry experts, and successful entrepreneurs, the company boasts a core team with both strong research capabilities and extensive commercialization experience. Leveraging its proprietary and cutting-edge proteomics technologies, DeepKinase has developed and commercialized advanced targeted proteomics products and holds intellectual property for its SH2 super-affinity enrichment technology. The company has independently developed platforms and product lines such as DoTK®, QSure®, and DoDT®. It has established partnerships with multiple hospitals and leading companies, expanding its reach into the Beijing-Tianjin-Hebei region, the Yangtze River Delta, and the North American market, and has completed several rounds of funding amounting to hundreds of millions.
Core Business: The company’s primary business includes:
DoTK: Utilizing unique patented technology to analyze tyrosine phosphorylation states, aiding in the understanding of kinase activity and signaling in cancer and immune diseases. DeepKinase has developed several proprietary technologies (with PCT patents) beyond DoTK® (TKI Drug Target Efficacy Proteomics Analysis Platform). These include:
DoTD: PROTAC and molecular glue drug degradation efficacy proteomics analysis platform
DoTF: General drug target analysis platform based on chemical proteomics technology
DoTB: Efficacy biomarker discovery platform based on plasma proteomics technology
These platforms and services cover areas such as MOA analysis, off-target and mis-target analysis, biomarker discovery and validation, precision patient stratification, indication expansion, and companion diagnostic development.
Technical Advantages:
High-Depth and High-Throughput Detection of Key Target Proteins: Achieves deep and extensive analysis of critical target proteins.
High Affinity for pTyr: Affinity for pTyr is increased by a factor of a thousand.
High Throughput: Provides comprehensive results in a single test.
Cost-Effective Large-Scale Production: Capable of large-scale expression and purification at a low cost.
Discovery of Novel Tyrosine Phosphorylation Sites: Identifies new biomarkers and targets.
Fully Proprietary Core Technology: Global PCT patents.
Traditional phosphorylation antibody detection techniques require starting from the complete protein structure, which imposes significant limitations on sample types and reduces clinical accessibility. In contrast, DeepKinase’s DoTK® technology platform overcomes these limitations. It is not affected by sample protein denaturation, allowing detection from a wider range of sample types, including fresh frozen tissues, formalin-fixed samples, and paraffin-embedded sections. This enhancement provides stronger clinical accessibility, facilitating the collection of comprehensive functional activity data and immunoactivity data from clinical samples.
Market Positioning: DeepKinase serves global pharmaceutical companies, biotechnology firms, and medical research institutions, focusing on providing high-quality proteomics analysis services. The company has established a robust collaborative network in the global market, actively expanding its international business, with significant market potential in BRICS countries.
Future Vision: DeepKinase aims to become a global leader in the field of proteomics analysis. In the future, the company will continue to increase its investment in R&D, drive technological innovation, and expand its international market presence, supporting the advancement of precision and personalized medicine. Additionally, the company will actively fulfill its corporate social responsibility, promoting progress in medicine and health, improving public health levels, and contributing to sustainable societal development.